Benitec Biopharma (NASDAQ:BNTC) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
Separately, Maxim Group reiterated a “hold” rating on shares of Benitec Biopharma in a research note on Wednesday, August 30th.
Benitec Biopharma (NASDAQ:BNTC) traded up $0.13 on Friday, reaching $3.03. 13,560 shares of the company’s stock were exchanged, compared to its average volume of 41,271. Benitec Biopharma has a 1 year low of $1.30 and a 1 year high of $5.48.
WARNING: “Benitec Biopharma (BNTC) Downgraded to Sell at ValuEngine” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/03/benitec-biopharma-bntc-downgraded-to-sell-at-valuengine.html.
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with MarketBeat.com's FREE daily email newsletter.